Soligenix Inc. (NASDAQ: SNGX) announced that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behçet's disease. This milestone paves the way for the European Commission to grant orphan drug designation, which could provide significant incentives for the development of this therapy.
According to the company, the positive opinion validates the scientific rationale behind dusquetide, an innate defense regulator designed to modulate the body's innate immune system rather than suppress it. For patients with rare inflammatory diseases like Behçet's disease, such regulatory progress can transform stalled research into meaningful therapeutic options.
"We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program," said Soligenix CEO and president Christopher J. Schaber, PhD. The designation offers incentives including protocol assistance, reduced regulatory fees, and up to 10 years of market exclusivity following approval.
Behçet's disease is a chronic, relapsing inflammatory condition that affects multiple organ systems, including the mouth, genitals, eyes, skin, joints, and blood vessels. There is currently no cure, and available treatments often have limited efficacy or significant side effects. Dusquetide's novel mechanism of action, which targets the innate immune system, holds promise for addressing this unmet medical need.
Soligenix is a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need. The company's pipeline includes several programs in various stages of development, with dusquetide being one of the most advanced. The orphan drug designation in Europe would complement existing orphan designations in the United States, further strengthening the company's regulatory strategy.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
